Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Zenas BioPharma, Inc. (NASDAQ:ZBIO) has received an average rating of “Moderate Buy” from the nine brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $44.2857.

A number of brokerages have commented on ZBIO. Morgan Stanley boosted their price objective on shares of Zenas BioPharma from $21.00 to $22.00 and gave the stock an “equal weight” rating in a report on Thursday, May 14th. Citigroup restated a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Weiss Ratings lowered Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. Zacks Research upgraded Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Finally, Wall Street Zen raised Zenas BioPharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th.

Zenas BioPharma Stock Down 2.3%

Shares of ZBIO traded down $0.69 during mid-day trading on Friday, reaching $28.74. 959,989 shares of the stock traded hands, compared to its average volume of 1,066,431. The stock has a fifty day simple moving average of $20.91 and a 200 day simple moving average of $22.75. Zenas BioPharma has a 12-month low of $11.00 and a 12-month high of $44.60. The company has a quick ratio of 11.94, a current ratio of 11.94 and a debt-to-equity ratio of 1.04. The firm has a market cap of $1.81 billion, a price-to-earnings ratio of -3.39 and a beta of -0.96.

Zenas BioPharma (NASDAQ:ZBIO) last announced its earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.01. During the same quarter in the previous year, the company earned ($0.80) earnings per share. Sell-side analysts expect that Zenas BioPharma will post -4.47 EPS for the current fiscal year.

Insider Activity

In other Zenas BioPharma news, CEO Leon O. Moulder, Jr. bought 60,000 shares of the business’s stock in a transaction on Monday, May 18th. The shares were bought at an average cost of $16.88 per share, with a total value of $1,012,800.00. Following the transaction, the chief executive officer directly owned 96,928 shares in the company, valued at approximately $1,636,144.64. This trade represents a 162.48% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Over the last quarter, insiders purchased 120,000 shares of company stock valued at $2,080,000. Corporate insiders own 22.00% of the company’s stock.

Institutional Trading of Zenas BioPharma

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Zenas BioPharma by 25.0% in the fourth quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock valued at $52,761,000 after acquiring an additional 290,307 shares in the last quarter. NEXTBio Capital Management LP bought a new position in Zenas BioPharma during the 4th quarter valued at $11,691,000. EcoR1 Capital LLC acquired a new position in Zenas BioPharma during the 4th quarter worth $28,667,000. Polar Capital Holdings Plc acquired a new position in Zenas BioPharma during the 4th quarter worth $38,402,000. Finally, iA Global Asset Management Inc. bought a new stake in shares of Zenas BioPharma in the 1st quarter worth about $4,219,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.